STLN · Starling Oncology, Inc.

Current Thesis

The narrative leg is a community-oncology operator converting itself into a risk-bearing, capitated platform, and the August print was the first quarter where that conversion showed up in margin rather than in slideware. Q2 2026 (quarter ended 2026-06-30, released 2026-08-06): revenue $161.3M against $119.8M a year earlier (+34.6%), gross profit $27.2M against $17.5M (+55.2%), adjusted EBITDA a positive $229 thousand versus negative $4.1M in Q2 2025, and net loss narrowed to $9.8M from $17.0M, or $(0.08) per share from $(0.15). Management raised full-year 2026 revenue guidance to $650–670M from $630–650M and gross profit to $105–110M from $97–107M in the same release.

Gross profit growing 20.6 percentage points faster than revenue is the operative fact — it says the mix is shifting toward capitated dollars the company keeps rather than pass-through drug dollars it merely handles. Roughly 2.1 million lives sit under value-based contracts, with ~$150M of capitated revenue guided for 2026 and a medical loss ratio band of 80–90%.

The narrative is maturing — the story arrived in a compressed window (legal name change effective 2026-07-28, rebrand announced 2026-08-03, ticker moved from TOI to STLN on 2026-08-04, Q2 beat 2026-08-06, B. Riley to $11 from $8 on 2026-08-07), sell-side targets were reset inside 24 hours of the print, and the flow behind it has thinned since: the shares closed 2026-09-04 at $5.93, 11.0% below the $6.66 closing high, with RSI(14) at 41.7 and no company-dated event on the calendar until the Q3 report.

Bullish and bearish views on Starling Oncology, Inc.

The model's bull view on Starling Oncology, Inc. (STLN), in brief: Margin inflection is measured, not promised. The bear view: The balance sheet is the constraint. Cash and equivalents $41.1M against long-term debt, net of $79.9M as of 2026-06-30, with FY2026 adjusted EBITDA guided at only $2–7M. A company that just doubled its market value and needs capital has an obvious channel open to it. Adjusted… Both cases follow in full.

Bull Case

• Margin inflection is measured, not promised. Gross profit $27.2M in Q2 2026 versus $17.5M in Q2 2025 (+55.2%) on revenue up 34.6% — 8-K exhibit 99.1, filed with the 2026-08-06 release.
• First positive adjusted EBITDA quarter. +$229 thousand versus −$4.1M in Q2 2025, with Q3 2026 adjusted EBITDA guided to $500K–$1.5M in the same release — a second consecutive positive quarter would make the inflection a trend rather than a print.
• Guidance raised, not reaffirmed. FY2026 revenue to $650–670M, gross profit to $105–110M, adjusted EBITDA to $2–7M (from $0–9M, a narrowed band with a raised floor); free cash flow held at $5–15M. Dated 2026-08-06.
• Geographic proof outside the home market. First delegated contracts signed outside Florida — Nevada and Oregon — plus an exclusivity agreement with one of its largest partners across California, per the Q2 call on 2026-08-06. The Florida delegated model was the single-state question; two new states and a California exclusive are the first answer.
• Specialty Pharmacy scaling fast. $98.6M of Q2 revenue, +58% YoY, on record Part D fills as new capitated lives onboard.
• Sell-side reset upward the same week. B. Riley raised its price target to $11 from $8 on 2026-08-07; the consensus target moved to $8.40 on updated capitated-revenue expectations, and the five-analyst average sits at $9.00 (stockanalysis.com, retrieved 2026-09-05) against the 2026-09-04 close of $5.93.

Bear Case

• The balance sheet is the constraint. Cash and equivalents $41.1M against long-term debt, net of $79.9M as of 2026-06-30, with FY2026 adjusted EBITDA guided at only $2–7M. A company that just doubled its market value and needs capital has an obvious channel open to it.
• Adjusted EBITDA of $229 thousand is a rounding error, and GAAP is still red. Net loss $9.8M in Q2 2026. The inflection headline rests on a non-GAAP measure barely above zero.
• Revenue quality is not uniform. Specialty Pharmacy contributed $98.6M of $161.3M in Q2 — drug-dispensing revenue carries thin margin, so headline growth can accelerate while gross profit dollars do not follow.
• Capitated risk cuts the other way. The guided medical loss ratio band is 80–90%; a book of 2.1 million lives with a bad utilisation quarter converts the margin story into a cost-trend story with no lag.
• Concentration. Florida delegated arrangements plus the newly-exclusive California partner mean a small number of counterparties drive the capitated ramp; Nevada and Oregon are new and unproven.
• Coverage is thin and retail-facing. Five covering analysts; the name's post-print appearances were in generic Benzinga "Health Care Stocks Moving" screens (2026-08-07 pre-market and intraday, 2026-08-28 after-market) rather than in fresh institutional initiations.

Setup & Price Structure

The 2026-09-04 close of $5.93 sits 11.0% under the $6.66 closing high on the adjusted daily series, with RSI(14) at 41.7 — momentum under the midline roughly four weeks after the event that created it. The three-month price change is +17.0%, while press coverage of the print described a ~33% single-session move on the Q2 beat and raised guidance (Kalkine, 2026-08-07). Most of the quarter's advance is that one repricing, and part of it has been handed back since; the shares are digesting a gap, not building on it.

Positioning observables, stated as observables: market capitalisation of roughly $604M on 101.92M shares outstanding (stockanalysis.com, retrieved 2026-09-05), a size at which one registered offering or one index flow sets the tape for a week. No Form 4 and no registered offering appeared in the filings reviewed for the period after the print — absence in a reviewed window, not a guarantee. There is no earnings date inside 30 days, so the name is in the flat part of its own calendar. The retail-facing movers coverage on 2026-08-07 and 2026-08-28 is the visible attention; nothing in the reviewed sources shows new institutional sponsorship arriving behind it.

The structure that would confirm the base is a weekly close back above $6.66, which would put the shares through the post-print closing high with the November report still ahead. The structure that would negate it is the consolidation shelf giving way on a weekly close below $5.25, which would return the shares beneath the range the August repricing established.

Catalyst Calendar (next 30 days)

• ~2026-11-05 (est.) — Q3 2026 results. Estimated from the 2026-08-06 Q2 cadence, not company-confirmed. This is the only hard test of the thesis: Q3 adjusted EBITDA was guided to $500K–$1.5M, and the FY2026 revenue band of $650–670M implies a second-half run-rate that Q3 either validates or does not.

No company-confirmed dated catalyst falls inside the next 30 days. The name spends the window on drift and sector beta.

Elapsed catalysts

• ~2026-09 (est., exact date unconfirmed in reviewed sources) — Wells Fargo Healthcare Conference participation, announced 2026-08-24. A fireside format is where the 2027 capitated-revenue framing gets restated or walked back; it is not a numbers event. (passed 13d ago)

What Would Change Our Mind

The margin relationship breaks first. Gross profit grew 55.2% on revenue growth of 34.6% in Q2 2026; if the Q3 print inverts that — revenue accelerating while gross profit dollars lag, as low-margin Specialty Pharmacy fills take more of the mix — then the re-rating from $8 to $11 targets loses the thing it was paid for, regardless of the top line. A medical loss ratio printing above the guided 80–90% band would do the same damage through the capitated book.

On price, a weekly close below $5.25 breaks the post-Q2 consolidation and puts the August revaluation back in play, since it returns the shares under the shelf that the print built. A cut to the FY2026 revenue guide of $650–670M or to the $2–7M adjusted EBITDA range at the Q3 report is the fundamental version of the same break.

The third path is quieter: the Wells Fargo appearance comes and goes in September with no new contract or capitated-lives disclosure, the November print lands in line rather than ahead, and the story completes its transition from repricing to consensus without a widening bid. That is not a crash — it is a name that stops paying for the attention it already received.

A registered equity offering priced into the post-print strength would be the clearest evidence that the $41.1M cash position against $79.9M of long-term debt drives the next corporate action rather than the operating ramp.

Correlation Notes

No theme cluster in the current registry carries this name, so it reads as a single-name setup rather than a group move — the thesis does not lean on a cohort trade, and any correlation here is exogenous rather than thematic.

Two shared drivers apply. First, the capitated book's economics track Medicare Advantage plan economics, which makes CMS rate policy a common factor with other risk-bearing provider groups; no CMS rate event was identified inside the next 30 days in the sources reviewed. Second, Specialty Pharmacy revenue of $98.6M in Q2 was driven by record Part D fills, so Part D benefit-design and reimbursement changes hit the largest revenue segment directly, and that exposure is shared with pharmacy-services names rather than with clinical-stage biotech.

The inference — flagged as inference, not measurement — is that this trades with small-cap healthcare services and risk-bearing provider sentiment rather than with the biotech complex, because the revenue is service and dispensing revenue, not trial-outcome optionality. Clinical trials & other contributed $3.8M of $161.3M in Q2 2026, which is the size of the biotech-adjacent exposure.